Ravulizumab
Ravulizumab | |
---|---|
Term | Ravulizumab |
Short definition | ravulizumab - (pronounced) (RAV-yoo-LIZ-yoo-mab) A medicine used to treat adults with paroxysmal nocturnal hemoglobinuria (a rare disease affecting red blood cells) and adults and children from 1 month of age with atypical haemolytic uremic syndrome (a very rare disease in which tiny blood clots form in small blood vessels). It is also being studied in the treatment of other conditions. |
Type | Cancer terms |
Specialty | Oncology |
Language | English |
Source | NCI |
Comments |
ravulizumab - (pronounced) (RAV-yoo-LIZ-yoo-mab) A medicine used to treat adults with paroxysmal nocturnal hemoglobinuria (a rare disease affecting red blood cells) and adults and children from 1 month of age with atypical haemolytic uremic syndrome (a very rare disease in which tiny blood clots form in small blood vessels). It is also being studied in the treatment of other conditions. Ravulizumab attaches to a protein in the immune system called C5. This can help prevent the breakdown of red blood cells and the formation of blood clots. Ravulizumab is a type of monoclonal antibody. Also called Ultomiris
External links
- Medical encyclopedia article on Ravulizumab
- Wikipedia's article - Ravulizumab
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski